• CanSino Biologics initiated a Phase I/II study for its 24-valent pneumococcal conjugate vaccine candidate, PCV24, with the first patient enrolled.
• No clinical results have been presented; the trial will generate future safety and immunogenicity readouts.
• The study targets people aged at least 6 weeks, aiming to broaden protection against pneumococcal disease across 24 serotypes.
• China’s NMPA cleared the trial in January 2026, extending the company’s pneumococcal franchise following iPneucia’s June 2025 approval.
• The program addresses a market gap, with no 24-valent pneumococcal conjugate vaccine currently marketed globally.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cansino Biologics Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260526-12170046), on May 26, 2026, and is solely responsible for the information contained therein.